AIM
MBRX icon

Acrospire Investment Management’s Moleculin Biotech MBRX Stock Holding History

Acrospire Investment Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1
Closed -$3K – 2382
2017
Q1 		$3K Buy
+1
New +$3.5K ﹤0.01% 2072
2016
Q4 		– Sell
-1
Closed -$9K – 2334
2016
Q3 		$9K Buy
+1
New +$14.4K 0.01% 1727

Other funds holding MBRX

VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acrospire Investment Management's MBRX Position: Q2 2017 in Review

Acrospire Investment Management sold out of Moleculin Biotech (MBRX) in Q2 2017, closing a stake of 1 share — an estimated $3K sold.

Acrospire Investment Management first reported a position in MBRX in Q3 2016 and held it in 2 quarters. The position peaked at $9K in Q3 2016. 13 funds tracked by Wall St. Rank hold MBRX as of Q2 2017.

  • Acrospire Investment Management reported no remaining Moleculin Biotech position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1 Moleculin Biotech share in Q2 2017, an estimated $3K.
  • Acrospire Investment Management first reported a position in Moleculin Biotech in Q3 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Moleculin Biotech position peaked at $9K in Q3 2016.
  • 13 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.